samedan logo
 
 
 
spacer
home > ebr > autumn 2016 > in the genes
PUBLICATIONS
European Biopharmaceutical Review

In the Genes

Many people take pleasure in knowing that the phrase “D’oh” originates from the TV series ‘The Simpsons’, whereas those who really know smugly attribute it to Jimmy Finlayson from the Laurel and Hardy films of the 1920s and 1930s. In much the same way, many people think that stem cells and gene-editing are also new inventions. Indeed, if one were to anthropomorphise two of the newest biotechnology tools, most people would regard stem cell technology as a junior-school prodigy, and its younger brother, gene-editing, as a precocious preschooler.

This year, 2016, does indeed mark the tenth anniversary of the first description of pluripotent stem cells induced from mammalian adult fibroblast cultures by defined factors – and fewer than four years ago, a programmable, dual-RNA-guided DNA endonuclease called Cas9 caught the imagination of thousands of laboratories across the globe. Variants of these tools have enjoyed a long and successful history, winning Nobel prizes and saving lives long before their current incarnations were even a glint in their inventors’ eyes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patrick Harrison is a Molecular Biologist at University College Cork, and his research is sponsored by the Cystic Fibrosis Trust. He began using gene-editing as a research tool for rare diseases in 2005, and his group was the first to publish a gene-editing strategy to correct the most common CF mutation in cells using ZFNs. His lab is currently using CRISPR-Cas9 and Cpf1 to study CF and other rare diseases, including cystinosis and epidermolysis bullosa.
spacer
Patrick Harrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gyros Protein Technologies and Cygnus Technologies Expand Collaboration to Support Improved Bioprocess Impurity Analytics, and Introduce HEK 293 HCP Assay Reagent Set for Gyrolab

Uppsala, Sweden: Gyros Protein Technologies (part of Mesa Labs’ Biopharmaceutical Development Division), a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the next phase of its on-going collaboration with Cygnus Technologies, a Maravai LifeSciences company.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement